Giuseppina Liuzzi,Carmela Pinnetti,Marco Floridia et al.
Giuseppina Liuzzi et al.
Background: There is limited information on pregnancy outcomes in women with HIV who are of a more advanced maternal age. Methods: Data...
Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function [0.03%]
.maraviroc在肾功能不全的HIV阴性受试者中的药代动力学、安全性和耐受性研究
Manoli Vourvahis,Juanzhi Fang,Tina Checchio et al.
Manoli Vourvahis et al.
Purpose: This open-label, nonrandomized, parallel-group study was conducted to explore the pharmacokinetics, safety, and tolerability of maraviroc in renally impaired subjects. ...
Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients [0.03%]
每日一次400毫克埃替拉韦治疗初治患者的药代动力学和药效学特征
Giovanni Di Perri,Bruce Green,Glynn Morrish et al.
Giovanni Di Perri et al.
Background: Etravirine is currently approved for HIV treatment-experienced patients at a dose of 200 mg twice daily. The long terminal elimination half-life of etravirine should support once-daily dosing. ...
Randomized Controlled Trial
HIV clinical trials. 2013 May-Jun;14(3):92-8. DOI:10.1310/hct1403-92 2013
Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies [0.03%]
利匹韦林与依非韦伦治疗接受恩曲他滨/富马酸替诺福韦二吡甲酯治疗的 HIV-1 感染者：ECHO 和 THRIVE 研究的汇总 96 周数据
M R Nelson,R A Elion,C J Cohen et al.
M R Nelson et al.
Objectives: Week 96 efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) was compared to efavirenz (EFV) in subset of 1,096 subjects who received emtricitabine/tenofovir diso...
Clinical Trial
HIV clinical trials. 2013 May-Jun;14(3):81-91. DOI:10.1310/hct1403-81 2013
High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine [0.03%]
人乳头瘤病毒疫苗多中心临床试验筛查出的HIV-1感染者高grade肛门上皮内瘤变
Timothy Wilkin,Jeannette Y Lee,Shelly Y Lensing et al.
Timothy Wilkin et al.
Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. ...
Clinical Trial
HIV clinical trials. 2013 Mar-Apr;14(2):75-9. DOI:10.1310/hct1402-75 2013
Measurement issues in using pharmacy records to calculate adherence to antiretroviral drugs [0.03%]
用药依从性测量中的问题及使用药房记录计算抗逆转录药物的用药依从性
Deanna E Grimes,Roberto A Andrade,Chad R Niemeyer et al.
Deanna E Grimes et al.
Background: Researchers often use pharmacy records to calculate adherence to antiretrovirals. Variability in the findings may be due to inconsistent methods of calculating adherence. ...
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment [0.03%]
高效抗逆转录病毒治疗期间的免疫激活可以预测治疗15年内的CD4+t细胞增加情况
Xinyan Zhang,Peter W Hunt,Scott M Hammer et al.
Xinyan Zhang et al.
Background: While persistent T-cell activation has been cross-sectionally associated with poor CD4+ T-cell restoration in HIV-infected individuals maintaining antiretroviral treatment (ART)-mediated viral suppression, it ...
Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial [0.03%]
维生素D缺乏的HIV感染青年口服胆钙化醇补充治疗对维生素D状态及T细胞表型的影响：一项随机对照试验
Vania Giacomet,Alessandra Vigano,Valeria Manfredini et al.
Vania Giacomet et al.
Objectives: In addition to its known effects on bone metabolism, vitamin D may regulate immune function. Design: We performed a randomi...
Randomized Controlled Trial
HIV clinical trials. 2013 Mar-Apr;14(2):51-60. DOI:10.1310/hct1402-51 2013
Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial [0.03%]
达芦那韦/利托那韦单药疗法与高效联合抗逆转录病毒标准治疗相比，144周时细胞内HIV-1 DNA动态变化：MONET试验
Anna Maria Geretti,Jose R Arribas,Erkki Lathouwers et al.
Anna Maria Geretti et al.
Background: In patients receiving combination antiretroviral therapy (ART), switching to monotherapy with ritonavir-boosted darunavir (DRV/r) can maintain plasma HIV-1 RNA suppression with no treatment-emergent drug resis...
Randomized Controlled Trial
HIV clinical trials. 2013 Jan-Feb;14(1):45-50. DOI:10.1310/hct1401-45 2013
HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam [0.03%]
越南胡志明市一线高效抗逆转录病毒治疗失败成人的人免疫缺陷病毒Ⅰ型耐药及影响因素分析
Quang Duy Pham,Thu Khanh Hoang Huynh,Tram Thu Luong et al.
Quang Duy Pham et al.
Background & objectives: Little is known about HIV-1 drug resistance (HIVDR) in people failing first-line highly active antiretroviral therapy (HAART) in Vietnam. The aim of this study was to investigate the frequency of ...